RxDoctor Payments Data

Guillermo Gonzalez Osete, MD

Hematology & Oncology · Tucson, AZNPI 1740249986

Payments from drug & device makers

$9,470in general payments, 2019–2025

Across 65 payments — averaging $145.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$4K
  • E.r. Squibb & Sons, L.L.C.$4K
  • Pfizer$141
  • Incyte Corporation$123
  • Novartis$115
  • Merck$112
  • plus $659 from 18 others

What the payments were for

  • Food & beverage$1,26193%
  • Education$907%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,470 in reported general payments places this provider in the 35th percentile of 261 hematology & oncology providers in Arizona.

See all hematology & oncology providers in Arizona

Medicare billing

Part B allowed, 2024
$976,012
Medicare patients
289
Services billed
50,998

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide127$2,141,384
CalquenceAcalabrutinib Maleate38$477,215
IbrancePalbociclib24$385,513
ImbruvicaIbrutinib36$380,773
XtandiEnzalutamide27$373,122
Lenalidomide21$270,750
PromactaEltrombopag Olamine24$228,771
ErleadaApalutamide25$201,788
TasignaNilotinib Hcl15$165,789
NubeqaDarolutamide13$164,978
KisqaliRibociclib Succinate11$145,891
Exemestane90$14,717
Imatinib Mesylate16$6,411
Cyclosporine11$2,934
Bicalutamide58$1,666

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$4,238$2,141,384127 claims
NovartisPromacta, Tasigna, Kisqali$115$540,45150 claims
AstraZenecaCalquence$39$477,21538 claims
PfizerIbrance$141$385,51324 claims
Johnson & JohnsonErleada$59$201,78825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 261 hematology & oncology providers in Arizona.

Other hematology & oncology in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →